Mr. Grassley has struggled to win Republican support for his drug-pricing legislation, largely due to the provision that would penalize drugmakers that raise prices faster than inflation.
This week Politico reported that Mr. Grassley had sharp words for the pharmaceutical industry and some of his Republican colleagues about the resistance to his legislation.
“People are fed up with big increases in drug prices,” he told Politico. “There’s 22 Republicans up for election, and [people] need an answer to that.”
Mr. Grassley is arguing that his bill, drafted in partnership with Ron Wyden (D-Ore.), is the only one with any real shot of passing in the Senate. He is attempting to get Republican senators on board by saying drugmakers can still recoup their investment by using the right launch price.
“We’re only saying, once you get your money back, you have to keep your prices reasonable,” he told lawmakers.
More articles on pharmacy:
Walgreens secures enterprisewide specialty accreditation
Drug price hike update: Merck, Allergen, Novartis raise prices
Regeneron restructures, cuts at least 15 jobs
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
